activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China Free

Abstract

To evaluate the antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 nonduplicate isolates (23.7 % isolated from HAP, 46.8 % from SSTI and 29.5 % from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant , 867 methicillin-sensitive , 299 coagulase-negative (CoNS), 104 , 99 , 13 , 23 α-haemolytic and 103 β-haemolytic . MICs of routine clinical antibiotics were determined by broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines 2015. Tedizolid, linezolid, vancomycin, daptomycin, teicoplanin and tigecycline showed high activity against Gram-positive pathogens (≥98.0 % susceptible), and tedizolid exhibited four- to eight fold greater activity than linezolid against the pathogens tested, with MICs of methicillin-resistant , α-haemolytic and β-haemolytic (0.25 vs 2 µg ml); methicillin-sensitive , and (0.5 vs 2 µg ml); methicillin-resistant CoNS and methicillin-sensitive CoNS (0.25 vs 1 µg ml); and (0.125 vs 0.5 µg ml). Tedizolid MICs associated with different infections did not show significant differences, and the drug exhibited excellent activity against surveyed Gram-positive pathogens associated with HAP, SSTI and BSI, including linezolid-nonsusceptible strains. These data suggest that tedizolid could be an alternative to linezolid for the treatment of infections caused by Gram-positive organisms.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000347
2016-10-18
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/10/1215.html?itemId=/content/journal/jmm/10.1099/jmm.0.000347&mimeType=html&fmt=ahah

References

  1. Burdette S. D., Trotman R. 2015; Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis 61:1315–1321 [View Article][PubMed]
    [Google Scholar]
  2. CLSI 2015 Performance Standards for Antimicrobial Susceptibility Testing; 25th Informational Supplement. Approved Standard M07-A10 , 10th edn. Wayne, PA: Clinical and Laboratory Standard Institute;
    [Google Scholar]
  3. Das D., Tulkens P. M., Mehra P., Fang E., Prokocimer P. 2014; Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis 58:S51–S57 [View Article][PubMed]
    [Google Scholar]
  4. Douros A., Grabowski K., Stahlmann R. 2015; Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 11:1849–1859 [View Article][PubMed]
    [Google Scholar]
  5. FDA 2014; Center for drug evaluation and research. application number: 205435Orig1s000 Microbiology / Virology review(S). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MicroR.pdf
  6. Guo Y., Wang H., Zhao C., Wang Z., Zhang F., Cao B., Hu B., Liao K., Mei Y. et al. 2012; Antimicrobial resistance surveillance of gram-positive cocci isolated from 14 hospitals in China in 2011. Chin J Lab Med 35:1021–2028 (in Chinese)
    [Google Scholar]
  7. Guo Y., Wang H., Zhao C., Wang Z., Cao B., Xu Y., Hu B., Ni Y., Zhang L. et al. 2013; A surveillance study of antimicrobial resistance of gram-positive cocci strains isolated from 16 teaching hospitals in China in 2012. Chin J Microbiol Immunol 33:401–409 (in Chinese)
    [Google Scholar]
  8. Guo Y., Wang H., Zhao C., Zhang F., Wang Z., Cao B., Xu Y., Chen M., Hu B. et al. 2015; Antimicrobial resistance surveillance of gram-positive cocci isolated from 15 teaching hospitals in China in 2013. Chin J Lab Med 38:1–10 (in Chinese)
    [Google Scholar]
  9. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F. C. 1997; Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135–136 [View Article][PubMed]
    [Google Scholar]
  10. Kanafani Z. A., Corey G. R. 2012; Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 21:515–522 [View Article]
    [Google Scholar]
  11. Kisgen J. J., Mansour H., Unger N. R., Childs L. M. 2014; Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm 71:621–633 [View Article][PubMed]
    [Google Scholar]
  12. Leclercq R., Derlot E., Duval J., Courvalin P. 1988; Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium . N Engl J Med 319:157–161 [View Article][PubMed]
    [Google Scholar]
  13. Moellering R. C. 2003; Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135–142 [View Article][PubMed]
    [Google Scholar]
  14. Moran G. J., Fang E., Corey G. R., Das A. F., De Anda C., Prokocimer P. 2014; Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14:696–705 [View Article][PubMed]
    [Google Scholar]
  15. Prokocimer P., Bien P., Surber J., Mehra P., DeAnda C., Bulitta J. B., Corey G. R. 2011; Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 55:583–592 [View Article][PubMed]
    [Google Scholar]
  16. Prokocimer P., De Anda C., Fang E., Mehra P., Das A. 2013; Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309:559–569 [View Article][PubMed]
    [Google Scholar]
  17. Rice L. B. 2006; Antimicrobial resistance in gram-positive bacteria. Am J Med 119:S11–19 [View Article][PubMed]
    [Google Scholar]
  18. Sahm D. F., Deane J., Bien P. A., Locke J. B., Zuill D. E., Shaw K. J., Bartizal K. F. 2015; Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 81:112–118 [View Article][PubMed]
    [Google Scholar]
  19. Shaw K. J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C. M., Shinabarger D., Zurenko G. 2008; In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 52:4442–4447 [View Article][PubMed]
    [Google Scholar]
  20. Sievert D. M., Ricks P., Edwards J. R., Schneider A., Patel J., Srinivasan A., Kallen A., Limbago B., Fridkin S. National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities 2013; Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1–14 [View Article][PubMed]
    [Google Scholar]
  21. Stryjewski M. E., Corey G. R. 2014; Methicillin-resistant Staphylococcus aureus: an evolving pathogen. Clin Infect Dis 58:S10–S19 [View Article][PubMed]
    [Google Scholar]
  22. Tsai H. Y., Liao C. H., Chen Y. H., Lu P. L., Huang C. H., Lu C. T., Chuang Y. C., Tsao S. M., Chen Y. S. et al. 2012; Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline in vitro surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob Agents Chemother 56:3402–3405 [View Article][PubMed]
    [Google Scholar]
  23. Winston L. G., Perlman J. L., Rose D. A., Gerberding J. L. 1999; Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis 29:580–585[PubMed] [CrossRef]
    [Google Scholar]
  24. Woodford N., Livermore D. M. 2009; Infections caused by gram- positive bacteria: a review of the global challenge. J Infect 59:S4–16 [View Article][PubMed]
    [Google Scholar]
  25. Zhanel G. G., Love R., Adam H., Golden A., Zelenitsky S., Schweizer F., Gorityala B., Lagacé-Wiens P. R., Rubinstein E. et al. 2015; Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs 75:253–270 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000347
Loading
/content/journal/jmm/10.1099/jmm.0.000347
Loading

Data & Media loading...

Most cited Most Cited RSS feed